Actions following adverse drug events – how do these influence uptake and utilisation of newer and/or similar medications?
Author:
Publisher
Springer Science and Business Media LLC
Subject
Health Policy
Link
http://link.springer.com/content/pdf/10.1186/s12913-015-1165-9.pdf
Reference35 articles.
1. Qureshi ZP, Seoane-Vazquez E, Rodriguez-Monguio R, Stevenson KB, Szeinbach SL. Market withdrawal of new molecular entities approved in the United States from 1980 to 2009. Pharmacoepidemiol Drug Saf. 2011;20(7):772–7.
2. Urquhart J. Some key points emerging from the COX-2 controversy. Pharmacoepidemiol Drug Saf. 2005;14(3):145–7.
3. Arellano FM. The withdrawal of rofecoxib. Pharmacoepidemiol Drug Saf. 2005;14(3):213–7.
4. Stamatakis E, Weiler R, Ioannidis JP. Undue industry influences that distort healthcare research, strategy, expenditure and practice: a review. Eur J Clin Invest. 2013;43(5):469–75.
5. McDonald CJ, Kalisch Ellett LM, Barratt JD, Caughey GE. An international comparison of spontaneous adverse event reports and potentially inappropriate medicine use associated with dabigatran. Pharmacoepidemiol Drug Saf. 2014;24(4):399–405.
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Impact of risk minimisation measures on the use of strontium ranelate in Europe: a multi-national cohort study in 5 EU countries by the EU-ADR Alliance;Osteoporosis International;2019-11-06
2. Adherence to Osteoporosis Therapies;Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism;2018-09-28
3. In Situ Sensor Advancements for Osteoporosis Prevention, Diagnosis, and Treatment;Current Osteoporosis Reports;2016-11-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3